Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 years or more with history of cardiac ischemia related chest discomfort of \> 10 minutes duration \< 24 hours prior to randomization, and having at least 1 of the following A or B. Participants who are planned to undergo PCI will be the target participants.~  * A: Positive biomarkers \[Elevated troponin I or creatinine kinase MB isozyme greater than the site's upper limit of normal (ULN)\] at or before registration~ * B: Electrocardiogram (ECG) changes: ST segment depression \>= 0.1 mV (\>=1 mm), or transient (\<30 minutes) ST segment elevation \>= 0.1 mV (\>=1 mm) in at least 2 contiguous leads~* Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.~* Women of child-bearing potential (all postmenarchal women who are \<1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.~Exclusion Criteria:~* Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)~* Any serious illness or any condition that the investigator feels would pose a significant hazard to the participant if investigational therapy were initiated~* known hypersensitivity to any component of the current investigational product;~* Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment~* Member of the staff personnel directly involved with this study;~* Family member of the investigational study staff;~* History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days before enrollment~* History of a hemorrhagic stroke at any time~* Severe hypertension (systolic blood pressure \>200 mm Hg or diastolic blood pressure \>110 mm Hg) while receiving therapy;~* Major surgery within 2 weeks prior to enrollment~* Known platelet count \<100,000/mm\^3~* Uncontrolled cardiac arrhythmia;~* Known impairment of renal function (serum creatinine \>2.0 mg/dL \[\>176.8 umol/L\]), dysproteinemia, nephrotic syndrome, or other renal disease;~* Active or chronic hepatobiliary or hepatic disease, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) activity more than two times greater than the upper limit of the laboratory reference range~* Anticipated staged PCI~* Concurrent or anticipated treatment with warfarin, factor Xa inhibitor, direct thrombin inhibitor, or antiplatelet agents except aspirin and ticlopidine after enrollment~* Anticipated intracoronary brachytherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorapaxar 20 mg/1 mg (Type: EXPERIMENTAL): Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
- Vorapaxar 20 mg/2.5 mg (Type: EXPERIMENTAL): Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
- Vorapaxar 40 mg/1 mg (Type: EXPERIMENTAL): Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
- Vorapaxar 40 mg/2.5 mg (Type: EXPERIMENTAL): Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)

Based on this trial design, predict the completion outcome and termination type (if applicable).